C.R. Bard Inc., founded in 1907 and headquartered in Murray Hill, New Jersey, is a global leader in developing innovative medical technologies to improve patient outcomes. The company specializes in a wide array of medical products, including vascular, urology, surgical, and oncology devices.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| BCR 6.70% 2026-12-01 USDC.R. Bard Inc. | United States | 2026-12-01 | 6.700 | 5.41 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
C.R. Bard has been active in the bond market since the 1980s, using debt financing to support its growth and product development initiatives. Significant issuances include their 2015 $500 million notes to fund acquisitions, which were well-received and solidified their market position. Current bond yields for Bard are competitive within the medical device sector, providing attractive options for retail investors. Notably, in 2017, Bard was acquired by Becton, Dickinson and Company, leading to adjustments in its bond structure, but the company continues to maintain a strong presence in the capital markets.